Halucenex partners with Nucro-Technics to test psilocybin efficacy in treatment-resistant PTSD


  • Halucenex Life Sciences has partnered with Nucro-Technics to assess synthetic psilocybin’s efficacy in treatment-resistant Post Traumatic Stress Disorder (PTSD).
  • With this agreement, the Company will develop and validate methods for potency, component identification, as well as microbiology for its botanical mushrooms.
  • The proposed Phase 2 study will determine the feasibility of upcoming trials of psilocybin for Treatment-Resistant PTSD.

Creso Pharma Limited (ASX:CPH, FRA:1X8) has announced that Halucenex Life Sciences Inc. had entered into an agreement with Nucro-Technics to provide microbiology and chemistry test work for a salient delivery solution by using synthetic psilocybin, which Halucenex is planning to use in the upcoming clinical trial submissions. Creso had signed an agreement to acquire Canada-based Halucenex in March 2021.

ALSO READ: Creso Pharma (ASX:CPH) sees an action-packed Q1 marked by Halucenex developments

Halucenex to assess the efficacy of psilocybin with Nucro-Technics

Under the agreement, Halucenex and Nucro-Technics will evaluate the stability and shelf life of liquid formulations of psilocybin for use in its Phase 2 clinical trial. Halucenex will have access to a Good Manufacturing Practice (GMP)-certified laboratory to prepare and assess its synthetic psilocybin compound.

Together, Halucenex and Nucro-Technics will evaluate psilocybin to:

Copyright © 2021 Kalkine Media Pty Ltd (Source: Source: CPH Announcement, 6 May 2021)

DO READ: Halucenex teams up with Sixth Wave; Californian legislation another leg-up for Creso Pharma

Key highlights:

  • The agreement will provide Halucenex with the ability to develop and validate methods for potency, component identification, as well as microbiology, for botanical mushrooms (psilocybe) grown at the Halucenex facility in the future.
  • NucroTechnics will receive a fee of CA$38,202 for the services specified under the agreement.
  • Halucenex can cancel the contract at any time by giving a written notice and payment of costs along with a reasonable cancellation fee agreed by both the parties.

Besides, as advised on 15 March 2021, Halucenex is waiting for Controlled Drugs and Substances Dealer’s License receipt from Health Canada. With the Dealers License receipt, Halucenex can apply for Clinical Trial Authorisation and start a Phase 2 clinical trial for the evaluation of psilocybin’s efficacy to treat Treatment-Resistant PTSD.

Nucro-Technics in a nutshell

  • Nucro-Technics is a Canada-based leading pharmaceutical contract research organisation.
  • The Canadian company partners with pharmaceutical, biologic, and medical device companies worldwide to assist with R&D initiatives.
  • The group has been running for ~50 years and employs more than 170 personnel, who manage a state-of-the-art 60K square foot facility in Toronto.
  • Nucro-Technics is compliant with multiple regulatory authorities, including Health Canada and the US FDA (Food and Drug Administration).

MUST READ: Creso Pharma (ASX:CPH) bolsters its presence in Africa with Cannabis Queen agreement

Proposed PTSD clinical trial

The proposed study will eventually evaluate the feasibility of upcoming trials of psilocybin to treat Treatment-Resistant PTSD.

The key highlights of the trial are-

  • Phase 2 trial is designed as a single-arm, open-lab study.
  • 18-20 individuals (over 18 years) suffering from Treatment-Resistant PTSD will be enrolled for the study.
  • The trial is anticipated to start in the third quarter of 2021, depending on the receipt of the required regulatory authorisations.

Additionally, Halucenex, through its strategic adviser David Fraser, has an association with Veterans Affairs Canada (VAC). The relationship will accelerate the revenue generation via sales into a market with substantial demand and government support.

DO READ: Creso Pharma welcomes milestone developments by acquisition target Halucenex

Management Commentary

Mr Bill Fleming, Founder and the CEO of Halucenex, commented-

Adding to this, Adam Blumenthal, Non-executive Chairman of Creso Pharma, stated-

On 10 May 2021, CPH shares last traded at AU$0.190 (at AEST 10:44 AM).

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK